Clinical Trials Browser

Phase 1/2 × Lymphoma, B-Cell, Marginal Zone × ibrutinib × Clear all

NCT02927964 2024-10-16

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Phase 1/2 Completed

21 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell